Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: A two-institution study

Seminars in Oncology

Volumn 30, Issue 2, 2003, Pages 226-230

  Bjorkholm M ^a,b   Johansson, E ^a,b   Papamichael, D ^a,b   Celsing, F ^a,b   Matthews, J ^a,b   Lister, T A ^a,b   Rohatiner, A Z S ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; DRUG RESPONSE; FEMALE; HEPATOSPLENOMEGALY; HUMAN; HYPOALBUMINEMIA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SPLENOMEGALY; STANDARD; SWEDEN; TEACHING HOSPITAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED KINGDOM; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0242684426     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50054     Document Type: Article

References (14)

1. Waldenström J: Incipient myelomatosis or "essential" hyperglobulinemia with fibrinogenopenia - A new syndrome? Acta Med Scand 117:216-247, 1944
2. Jaffe ES, Harris NL. Stein H, et al (eds): WHO Classification of Tumours. Tumours of Haematopoietic and Lymphoid Tissues. Pathology & Genetics. Lyon, France, IARC Press, 2001
3. Wagner SD, Martinelli V, Luzzatto L, et al: Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood 12:3647-3653, 1994
4. Herrinton LJ, Weiss NS: Incidence of Waldenstrom's macroglobulinemia. Blood 82:3148-3150, 1993
5. Gertz MA, Fonseca R, Rajkumar SV: Waldenstrom's macroglobulinemia. Oncologist 5:63-67, 2000
6. Facon T, Brouillard M, Duhamel A, et al: Prognostic factors in Waldenstrom's macroglobulinemia: A report of 167 cases. J Clin Oncol 11:1553-1558, 1993
7. Gobbi PG, Bettini R, Montecucco C, et al: Study of prognosis in Waldenstrom's macroglobulinemia: A proposal for a simple binary classification with clinical and investigational utility. Blood 83:2939-2945, 1994
8. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol. 18:214-226, 2000
9. Dhodapkar MV, Jacobson JL, Gertz MA, et al: Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: Results of United States intergroup trial (Southwest Oncology Group S9003). Blood 98:41-48, 2001
10. Owen RG, Barrans SL, Richards SJ, et al: Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 116:420-428, 2001
11. Morel P, Monconduit M, Jacomy D, et al: Prognostic factors in Waldenström macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 96:852-858, 2000
12. Papamichael D, Norton AJ, Foran JM, et al: Immunocytoma: A retrospective analysis from St Bartholomew's Hospital-1972 to 1996. J Clin Oncol 17:2847-2853, 1999
13. Kaplan HS, Meier P: Non-parametric estimation from incomplete observation. Am Stat Assoc J 53:457-480, 1958
14. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977